Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma
IntroductionDiffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. While Metabolic Syndrome (MetS) has been linked to NHL prognosis, its impact on DLBCL outcomes remains unc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1524498/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693966775091200 |
|---|---|
| author | Dewan Zhao He Xu Fengrao Tang Tongcheng Cui Xiuli Sun Guirong Song |
| author_facet | Dewan Zhao He Xu Fengrao Tang Tongcheng Cui Xiuli Sun Guirong Song |
| author_sort | Dewan Zhao |
| collection | DOAJ |
| description | IntroductionDiffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. While Metabolic Syndrome (MetS) has been linked to NHL prognosis, its impact on DLBCL outcomes remains unclear.MethodsThis study examined the effects of dynamic changes in MetS components on DLBCL treatment outcomes and prognosis. We retrospectively analyzed 125 newly diagnosed DLBCL patients treated with 6-8 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens, with or without rituximab, from May 2010 to May 2022. Group-based trajectory models were used to identify MetS component trajectories. Multivariate logistic regression and Cox proportional hazards regression were employed to determine factors affecting complete remission (CR), progression-free survival (PFS), and overall survival (OS).ResultsThe 2-year PFS and OS rates were 70.0% and 82.0%, respectively. High baseline high-density lipoprotein cholesterol (HDL-C) was associated with reduced progression risk (HR = 0.27, 95% CI: 0.10-0.78), while high baseline low-density lipoprotein cholesterol (LDL-C) was linked to decreased CR rate (OR = 0.65, 95% CI: 0.44-0.97) and increased progression risk (HR = 1.78, 95% CI: 1.14-2.79). Additionally, high LDL-C trajectory was associated with reduced CR rates, whereas moderate BMI trajectory was associated with improved CR, PFS, and OS.DiscussionTherefore, controlling LDL-C levels and maintaining a moderate BMI are crucial for improving DLBCL clinical outcomes. |
| format | Article |
| id | doaj-art-d5430c8d3b4a4fb5847ecd1a7a024c09 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-d5430c8d3b4a4fb5847ecd1a7a024c092025-08-20T03:20:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15244981524498Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphomaDewan Zhao0He Xu1Fengrao Tang2Tongcheng Cui3Xiuli Sun4Guirong Song5Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Health Statistics, School of Public Health, Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Health Statistics, School of Public Health, Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Health Statistics, School of Public Health, Dalian Medical University, Dalian, Liaoning, ChinaIntroductionDiffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. While Metabolic Syndrome (MetS) has been linked to NHL prognosis, its impact on DLBCL outcomes remains unclear.MethodsThis study examined the effects of dynamic changes in MetS components on DLBCL treatment outcomes and prognosis. We retrospectively analyzed 125 newly diagnosed DLBCL patients treated with 6-8 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens, with or without rituximab, from May 2010 to May 2022. Group-based trajectory models were used to identify MetS component trajectories. Multivariate logistic regression and Cox proportional hazards regression were employed to determine factors affecting complete remission (CR), progression-free survival (PFS), and overall survival (OS).ResultsThe 2-year PFS and OS rates were 70.0% and 82.0%, respectively. High baseline high-density lipoprotein cholesterol (HDL-C) was associated with reduced progression risk (HR = 0.27, 95% CI: 0.10-0.78), while high baseline low-density lipoprotein cholesterol (LDL-C) was linked to decreased CR rate (OR = 0.65, 95% CI: 0.44-0.97) and increased progression risk (HR = 1.78, 95% CI: 1.14-2.79). Additionally, high LDL-C trajectory was associated with reduced CR rates, whereas moderate BMI trajectory was associated with improved CR, PFS, and OS.DiscussionTherefore, controlling LDL-C levels and maintaining a moderate BMI are crucial for improving DLBCL clinical outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2025.1524498/fullbody mass indexHDL cholesterolLDL cholesteroldiffuse large B-cell lymphomametabolic syndrome |
| spellingShingle | Dewan Zhao He Xu Fengrao Tang Tongcheng Cui Xiuli Sun Guirong Song Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma Frontiers in Oncology body mass index HDL cholesterol LDL cholesterol diffuse large B-cell lymphoma metabolic syndrome |
| title | Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma |
| title_full | Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma |
| title_fullStr | Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma |
| title_full_unstemmed | Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma |
| title_short | Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma |
| title_sort | association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large b cell lymphoma |
| topic | body mass index HDL cholesterol LDL cholesterol diffuse large B-cell lymphoma metabolic syndrome |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1524498/full |
| work_keys_str_mv | AT dewanzhao associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma AT hexu associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma AT fengraotang associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma AT tongchengcui associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma AT xiulisun associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma AT guirongsong associationofdynamicchangesinmetabolicsyndromecomponentswithclinicaloutcomesindiffuselargebcelllymphoma |